Loading...
Please wait, while we are loading the content...
Similar Documents
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
| Content Provider | Scilit |
|---|---|
| Author | O’Brien, Susan Woyach, Jennifer A. Smucker, Kelly Smith, Lisa L. Lozanski, Arletta Zhong, Yiming Ruppert, Amy S. Lucas, David Williams, Katie Zhao, Weiqiang Rassenti, Laura Ghia, Emanuela Kipps, Thomas J. Mantel, Rose Jones, Jeffrey Flynn, Joseph Maddocks, Kami Furman, Richard R. James, Danelle F. Clow, Fong Lozanski, Gerard Johnson, Amy J. Byrd, John C. |
| Copyright Year | 2014 |
| Description | Key Points Persistent CLL cells during ibrutinib therapy show evidence of biochemical activation, but inhibited BCR and no proliferation. Long lymphocytosis during ibrutinib therapy is not associated with adverse progression-free survival. |
| Related Links | http://www.bloodjournal.org/content/bloodjournal/123/12/1810.full.pdf |
| Ending Page | 1817 |
| Page Count | 8 |
| Starting Page | 1810 |
| DOI | 10.1182/blood-2013-09-527853 |
| Journal | Blood |
| Issue Number | 12 |
| Volume Number | 123 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2014-03-20 |
| Access Restriction | Open |
| Subject Keyword | Research and Experimental Medicine Survival Cll Prolonged Therapy Is Associated Lymphocytosis During Ibrutinib Therapy Ibrutinib Therapy Is Not Associated Journal: Blood (Vol- 121, Issue- 12) |
| Content Type | Text |
| Resource Type | Article |